Latest Breaking News On - Biree andemariam - Page 5 : comparemela.com

HEMANEXT SUBMITS HEMANEXT ONE® SYSTEM TO FDA FOR U.S. MARKETING AUTHORIZATION

/PRNewswire/ Hemanext Inc., a leading innovator in blood processing and storage technology, announced that it submitted the Hemanext ONE® system for.

VC Daily: Expansion Therapeutics Gets $80 Million for RNA-Targeted Drugs

Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress

Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress - read this article along with other careers information, tips and advice on BioSpace

Life of Young Mom with Sickle Cell Disease Improved by New Drug

Life of Young Mom with Sickle Cell Disease Improved by New Drug Patients at UConn Health s New England Sickle Cell Institute have a range of advanced health management options available to them Brandy Compton, with her son Jermaine (contributed photo). Copy Link Since she was only 4 months old, Brandy Compton, 31, of Hartford, has been battling sickle cell disease, a painful inherited red blood cell condition impacting the blood’s circulation due to abnormally hook-shaped red blood cells. “As a baby I wouldn’t stop crying, and nothing my mother did worked to console me. Then they found out I had sickle cell disease,” says Compton. “Growing up was challenging, and I was homeschooled after the third grade since I was missing way too many days of school due to my painful disease.”

Global Blood Therapeutics, Inc.: GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress

New Oxbryta, taking place online June 9-17, 2021. Results from an analysis of the Phase 2a HOPE-KIDS 1 Study (GBT440-007) in children with SCD ages 4 to 11 years treated with Oxbryta (voxelotor) tablets